Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)
6.21
+0.01 (0.16%)
Feb 4, 2026, 10:25 AM CST
SHE:300039 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 778.83 | 593.31 | 601.94 | 694.69 | 1,345 | 1,307 |
Short-Term Investments | 662.99 | 924.87 | - | - | 58.32 | 36.13 |
Trading Asset Securities | 197.81 | 180.02 | 150.01 | 136.07 | 51.26 | 114.65 |
Cash & Short-Term Investments | 1,640 | 1,698 | 751.95 | 830.76 | 1,455 | 1,458 |
Cash Growth | 23.89% | 125.84% | -9.49% | -42.88% | -0.23% | 8.09% |
Accounts Receivable | 351.65 | 471.99 | 529.32 | 530.33 | 567.99 | 528.76 |
Other Receivables | 0.42 | 34.51 | 10.34 | 35.77 | 46.77 | 32.32 |
Receivables | 352.07 | 506.51 | 539.67 | 566.09 | 614.76 | 562.39 |
Inventory | 199.05 | 187.85 | 171.79 | 160.8 | 165.14 | 191.54 |
Other Current Assets | 39.91 | 22.81 | 11.47 | 16.77 | 19.99 | 8.08 |
Total Current Assets | 2,231 | 2,415 | 1,475 | 1,574 | 2,254 | 2,220 |
Property, Plant & Equipment | 259.41 | 267.85 | 290.09 | 304.66 | 307.78 | 295.87 |
Long-Term Investments | 1,390 | 1,624 | 2,730 | 1,312 | 711.06 | 280.24 |
Goodwill | - | - | - | 9.04 | 13.79 | 18.5 |
Other Intangible Assets | 164.9 | 168.8 | 45.11 | 44.23 | 42.9 | 45.26 |
Long-Term Deferred Tax Assets | 26.48 | 29.44 | 31.61 | 18.26 | 15.1 | 17.55 |
Long-Term Deferred Charges | 2.93 | 2.44 | 0.21 | 0.32 | - | - |
Other Long-Term Assets | 884.17 | 11.03 | 7.64 | 996.49 | 10.75 | - |
Total Assets | 4,958 | 4,518 | 4,580 | 4,259 | 3,356 | 2,877 |
Accounts Payable | 104.99 | 99.37 | 134.85 | 91.01 | 75.02 | 62.23 |
Accrued Expenses | 4.74 | 26.46 | 23.27 | 29.69 | 15.92 | 13.47 |
Short-Term Debt | 4.17 | 5.42 | - | - | - | 35.72 |
Current Income Taxes Payable | 38.18 | 31.62 | 41.08 | 35.54 | 3.47 | 8.82 |
Current Unearned Revenue | 13.84 | 18.29 | 45.69 | 40.04 | 2.88 | 1.75 |
Other Current Liabilities | 14.08 | 51.15 | 89.96 | 99.67 | 93.39 | 115.56 |
Total Current Liabilities | 180 | 232.3 | 334.85 | 295.96 | 190.68 | 237.55 |
Long-Term Unearned Revenue | 48.43 | 48.03 | 43.26 | 39.51 | 47.16 | 51.53 |
Long-Term Deferred Tax Liabilities | 184.13 | 135.11 | 168.71 | 162.77 | 73.06 | 9.88 |
Total Liabilities | 412.55 | 415.45 | 546.82 | 498.24 | 310.9 | 298.96 |
Common Stock | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 |
Additional Paid-In Capital | 8.62 | 8.62 | 8.62 | 8.62 | 8.62 | 8.62 |
Retained Earnings | 2,488 | 2,323 | 2,050 | 1,785 | 1,577 | 1,468 |
Comprehensive Income & Other | 1,002 | 724.5 | 926.33 | 921.98 | 413.53 | 55.68 |
Total Common Equity | 4,545 | 4,102 | 4,031 | 3,762 | 3,045 | 2,578 |
Minority Interest | 0.6 | 0.97 | 1.64 | -0.72 | -0 | - |
Shareholders' Equity | 4,546 | 4,103 | 4,033 | 3,761 | 3,045 | 2,578 |
Total Liabilities & Equity | 4,958 | 4,518 | 4,580 | 4,259 | 3,356 | 2,877 |
Total Debt | 4.17 | 5.42 | - | - | - | 35.72 |
Net Cash (Debt) | 1,635 | 1,693 | 751.95 | 830.76 | 1,455 | 1,422 |
Net Cash Growth | 23.85% | 125.12% | -9.49% | -42.88% | 2.28% | 5.44% |
Net Cash Per Share | 1.56 | 1.62 | 0.72 | 0.79 | 1.39 | 1.36 |
Filing Date Shares Outstanding | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 |
Total Common Shares Outstanding | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 |
Working Capital | 2,051 | 2,183 | 1,140 | 1,278 | 2,064 | 1,982 |
Book Value Per Share | 4.35 | 3.92 | 3.85 | 3.60 | 2.91 | 2.46 |
Tangible Book Value | 4,380 | 3,933 | 3,986 | 3,708 | 2,988 | 2,515 |
Tangible Book Value Per Share | 4.19 | 3.76 | 3.81 | 3.55 | 2.86 | 2.40 |
Buildings | - | 386.31 | 383.04 | 372.25 | 342.91 | 342.42 |
Machinery | - | 425.35 | 441.06 | 427.9 | 407.9 | 400.23 |
Construction In Progress | - | 1.23 | 0.52 | 6.18 | 34.15 | 1.99 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.